IRVINE, CA – May 6, 2011 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTC Markets: INKN), an innovative high technology innovation and development company announced today that it has signed a multi-phase joint development agreement with one of the world’s largest industrial and consumer electronics and optics companies, headquartered in Japan, and with offices for its biological components group in Salzburg, Austria. The agreement calls for Shrink and its partner to co-develop the final Corning commercial platform, and for Shrink’s joint venture partner to provide its unique engineering and manufacturing expertise in order to bring to market a modular microfluidic platform and interconnect system for targeted applications in the life science market.

Shrink CEO Mark L. Baum stated, “We are pleased to be working with one of the leading corporations in the world in order to commercialize the Corning modular microfluidic platform. Our partner is a world class provider of bioengineering solutions for Company’s like Shrink, and they are committed to developing and bringing to market innovative “smart consumables” for targeted applications in the life science market. Known throughout the world as a leading industrial and consumer electronics company, they bring a unique suite of capabilities in the design and manufacturing of ultra-precise high volume plastic consumables, skills that will contribute to this exciting opportunity.”

About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a FIGA™ organization, focusing on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and in all cases develops proprietary and patent-pending nano-sized technologies, components and product systems for a number of leading edge technology markets of varying sizes. For more information, please visit www.shrinknano.com.

Contact for Shrink Nanotechnologies, Inc.
Mark L. Baum
(760) 692-1160

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release due to a myriad of factors given the stage of development of Shrink. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Shrink is a development stage company and any investment in Shrink should only be made after (i) review of our public filings with the U.S. Securities and Exchange Commission (www.sec.gov), particularly the “Risk Factors” in our most recent Form 10-K, and (ii) after counsel from a registered investment professional.

IRVINE, CA – April 11, 2011 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTC Markets: INKN), an innovative high technology company, announced today that it has executed a binding letter of intent to acquire 100% of Hawaii-based Nanopoint Inc. (“Nanopoint”), a biomedical instrumentation and microfluidics company with global distribution for its award-winning suites of life sciences products.

The transaction highlights are:

• Shrink will exchange 25,750,000 shares of its common stock for 100% of the equity interests in Nanopoint;
• Additional stock payments of up to 40,000,000 shares will be made upon Nanopoint meeting certain sales and EBITDA targets by June 30, 2012 and December 31, 2013, respectively;
• All critical Nanopoint employees will be retained, and at closing, Nanopoint will operate as a wholly owned subsidiary of Shrink;
• Nanopoint will have not less than $500,000 of cash on its balance sheet; and
• The closing, which has been set for May 31, 2011 or sooner, is subject to additional terms and conditions as well as customary due diligence by the parties.

Shrink CEO Mark L. Baum stated, “We are pleased to have the opportunity to welcome the Nanopoint team to our family. Nanopoint has built an award-winning platform of products in the life sciences space, as well as a network of global distribution for its products. Nanopoint’s product line will extend Shrink’s portfolio of opportunities in the drug discovery, live cell imaging, assisted reproductive sciences, stem cell research and cell culturing businesses. We believe that there is tremendous synergy between our respective products – StemDisc and Cell Align, in particular, along with work that we are doing with the Corning modular microfluidics platform, and we believe that the Nanopoint distribution group is a terrific way for Shrink to leverage on the relationships that Nanopoint has been able to build.”

Nanopoint CEO Cathy Owen, stated, “Nanopoint has spent 6 years and over 6 million dollars building a world class extended live cell imaging platform and refining that platform along with our customers to meet the unique requirements of the assisted reproduction, drug discovery, and stem cell research markets. Nanopoint’s robust patent portfolio and collaborative partnerships will help keep us ahead of our competitors. Our growing network of highly respected distributors in Australia, Asia and Europe will enable us to provide innovative products to research scientists across the world. The acquisition by Shrink Nanotechnologies will provide the capital and liquidity necessary to rapidly accelerate sales of Nanopoint’s cellTRAY® Imaging System, cellTRAY® Microfluidics System, cellTRAY® Mini-Microscope System, and associated consumables including the patented cellTRAY® slide and newly patented cellTRAY® Dish.”

About Shrink Nanotechnologies, Inc.

Shrink Nanotechnologies, Inc. is a FIGA™ organization, focusing on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and in all cases develops proprietary and patent-pending nano-sized technologies, components and product systems for a number of leading edge technology markets of varying sizes. For more information, please visit www.shrinknano.com.

About Nanopoint Inc.

Nanopoint is a privately-held life sciences instrumentation and microfluidics platform company that is revolutionizing biomedical research with its extended time-lapse live cell imaging solutions. Nanopoint’s award-winning, patented cellTRAY®, patented cellTRAY® Dish, and patent-pending automated microfluidics delivery system, on-stage incubation system and proprietary imaging software provides solutions to a broad spectrum of applications including drug discovery, assisted reproductive technologies, lab-on-a-chip, stem cell research, and bio-detection. The cellTRAY® Imaging System has won major awards for innovation and design excellence: 1) 2010 GOOD Design Award-Medical Category, 2) 2010 Spark Award-Silver, 3) 2009 Frost and Sullivan North American Cell Imaging Solutions Product Innovation of the Year Award, 4) 2009 ID Magazine Annual Design Review Best of Category – Equipment, and 5) 2009 International Design Excellence Award Gold Medal Winner in Medical & Scientific Products, and 6) the 2009 and 2010 Best of Honolulu Award from the US Department of Commerce. For more information, please visit: www.nanopointimaging.com

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of Shrink Nanotechnologies and Nanopoint Imaging, Inc. and their respective management teams. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology technologies and products, including those discussed in this press release. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

Contact:
Shrink Nanotechnologies
Mark L. Baum, Esq.
760-804-8844 x205

CARLSBAD, CA – December 14, 2010 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB: INKN), an innovative nanotechnology company developing products and licensing opportunities in the solar energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today through its wholly owned subsidiary, BlackBox Semiconductor, Inc., that it’s recently licensed “electronic glue” chemistry will enable high efficiency solar cells to be fabricated from semiconductor nanocrystals with low cost roll-to-roll processing.

For years it has been theorized that the tunable properties of semiconductor nanocrystals could enable a next generation of highly efficient and low cost solar cells. However, to date, efficiencies of such devices have been extremely low – mostly due to the fact that the “electronic coupling” between nanocystals has been poor. This means that when energy is created, it does not flow very well – certainly not as well as silicon – which means that minimal amounts of the energy collected are ultimately harvested and turned into power. “Electronic glue” solves this critical technical barrier.

In a solar cell, light is harvested by the semiconductor material (typically silicon) which produces charges. In order to produce electricity, these charges need to flow easily through the material. Solar cells have been made from nanomaterials, but the efficiency improving properties of the nanomaterials have to be eliminated by melting them together because this is the only way for charge carriers to flow. Nanocrystals have been great light harvesters but have historically have provided a poor path for charges to flow.

The University of Chicago technology, invented by Dr. Dmitri Talapin, solves this problem by modifying the nanocrystals with an “electronic glue” that allows charges to flow more easily between particles, thus giving the device the potential power and efficiency of bulk semiconductors while enjoying the benefits of the small size and flexibility of the semiconductor nanocrystals. This will lead to a device being manufactured with the ultimate combination of high efficiency and low cost, roll-to-roll production.

“Shrink has done a considerable amount of work in the semiconductor nanocrystal realm, always running into the headwinds electronic coupling issues. We believe that Dr. Talapin’s “electronic glue” technology is going to be a game changer as we ready our resources to turn this technology into products that make a difference in people’s lives,” said Shrink CEO Mark L. Baum.
The Large and Growing Solar Market Needs a Game Changing Next Generation Commercial Technology

The global solar market is poised to rebound in the coming years and ultimately eclipse the $83 billion market in 2014, according to U.S. Solar Energy Market World Data, 2nd Edition by leading industrial market research firm SBI Energy.

Future growth is attributed to the anticipated strength of strong photovoltaic module sales in countries such as the United States, Germany, and China, in addition to a continuing strong solar thermal market in the two latter countries. Compound annual growth rate (CAGR) will exceed of 40% through 2014 in many segments of the solar market.

According to Norman Deschamps, SBI Energy analyst, “The strong growth for solar as a whole is going to begin in 2010 as sales in the photovoltaic sector continue to accelerate and declines in module and system component prices become far more moderate, along the lines of a 10% to 15% drop rather than the tumultuous 25% to 40% drop experienced in 2009. Equally noteworthy is the reality that global concentrated solar power installations are just getting started and we predict tremendous growth in the segment beginning in 2012.”

In the U.S., the solar market has come far since its inception over 30 years ago, but still has a long way to go. While growth has been spectacular since 2002, solar power continues to hold just a fractional share — under 1% — of U.S. energy production. Nevertheless, the U.S. has the greatest potential to increase its position in the solar market. The U.S. photovoltaic market was up an estimated 6% in 2009 to almost $4 billion and photovoltaic installations rose to 469 megawatts, according to SBI Energy. By 2014, photovoltaic installations are forecast to reach 7,600 megawatts by building on renewed interest in solar from utilities and the extension of the solar tax credit.

To learn more about Dr. Talapin’s work, Google: “electronic glue”

About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink licenses, owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company’s unique NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology and solar technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.
See also:

http://www.shrinksolar.com/blog/

http://www.shrinknano.com/products/product-tools

http://www.shrinknano.com/products/product-diagnostics

http://www.shrinknano.com/tech

http://www.shrinknano.com/tr35-a-children%E2%80%99s-toy-inspires-a-cheap-easy-production-method-for-high-tech-diagnostic-chips

New ‘electronic glue’ promises less expensive semiconductors
Dmitri Talapin

Shrink Nanotechnologies announced today that it had formed a wholly owned subsidiary called BlackBox Semiconductor, Inc. (“BlackBox”), and that BlackBox has entered into a worldwide multi-year exclusive license with the University of Chicago, licensing work based on Assistant Professor of Chemistry, Dmitri Talapin’s “electronic glue” chemistry. The license covers all applications except for thermoelectric applications.

“We are pleased to announce that we have reached an agreement with the University of Chicago to license intellectual property that we believe has the potential to radically change the economics in a number of burgeoning large industries, including printed semiconductors, roll-to-roll printed solar cells and a new generation of low cost printed nano-sensors. This technology and the ongoing work by its inventors is widely acclaimed and has been published on multiple occasions in the world’s most prestigious academic journals, including Science, Nature and the Journal of the American Chemical Society,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

Semiconductors have served as choice materials for many electronic and optical devices because of their physical properties. Semiconductor nanocrystals are mass-produceable and have promise for use in device manufacturing via inkjet printing and other solution-based processes.

Commercial solar cells, computer chips and other semiconductor technologies typically use large semiconductor crystals, such as silicon. These materials and the processes required to manufacture commercial products from them are expensive and can make large-scale applications such as rooftop solar-energy collectors prohibitive. Also, material such as silicon is not “tunable” which means they can only harness a relatively narrow part of the available solar spectrum.

While semiconductor nanocrystals are very good receptors of light which could be converted to electricity (in the case of a solar cell), the collection of electrical charges from individual semiconductor nanocrystals cannot be accomplished efficiently using existing technologies because the semiconductor nanocrystals themselves are not great “carriers” of the electricity produced by the light they receive.

Prior to Dr. Talapin’s innovation – which has been called “electronic glue” – nanocrystals were unable to efficiently transfer their electric charges to one another because of the surface ligands which are used in the nanocrystal synthesis process. These surface ligands are bulky, insulating organic molecules that cap nanocrystals. Dr. Talapin’s “electronic glue” solves the ligand problem by substituted insulating organic molecules with novel inorganic molecules and dramatically increases the electronic coupling between nanocrystals.

Baum concluded, “We have been working on nanocrystal applications since we started Shrink. We have an appreciation of the shortcomings of nanocrystals for these ‘killer apps’ like solar cells and other large market semiconductor applications. We believe what we have is the potential to build low cost tunable solid state semiconductors which perform like bulk semiconductors, but which maintain all of the tremendous benefits that semiconductor nanocrystals offer. This license is an important part of how we intend to drive value for our shareholders, as we build our business by executing on our unique model. Over the coming months, we will begin to discuss this powerful technology and our plans to deploy resources to develop targeted commercial applications with it.”

To learn more about Dr. Talapin’s work, Google: “electronic glue”

Shrink Nanotechnology announced today that it has entered into a multi-year development and manufacturing agreement with EV Group, a leader in the nano-imprint lithography process development and equipment manufacturing. The mutually exclusive, two year agreement calls for EV Group and Shrink to develop and manufacture Shrink’s structured substrates for its StemDisc stem cell and cell culturing platform.

“We are pleased to announce Shrink’s relationship with EV Group, a world-class nanotechnology applications developer and equipment manufacturer with a global presence. Over the past two years, Shrink StemDisc product footprint has served as a platform for our entry into the growing cell culturing business. We believe that StemDisc offers unique competitive advantages relative to its peers and are excited as an organization as we roll out our initial products later this year and into the first quarter of next year,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

Baum added, “Throughout the development process, we have counseled with EV Group and they have assisted us in creating manufacturing solutions that will allow Shrink to move from the prototype stage to the ability make many thousands of devices. As important, our relationship with EV Group has been structured for us to move beyond our initial product, the StemDisc450, as we add new products to the StemDisc family of products.”

Steven Dwyer, EV Group Inc., Vice President and General Manager of North America stated, “Our Agreement with Shrink follows many months of work between Shrink’s StemDisc development group and our staff in Tempe, Arizona. Our team’s dedication to meeting Shrink’s strict fabrication requirements demonstrates the success of our overall effort to develop our process services at our Tempe, AZ facility. This effort will ensure that Shrink has access to many thousands of StemDisc devices as soon as the end of this year, in an efficient and cost effective process, using EV Group’s state-of-the-art Applications Lab This project will hopefully be one of many we work on with Shrink as EV Group leverages its significant intellectual capital in the form of process and equipment development for small and medium sizes business around the world.”

About EV Group

EV Group (EVG) is a world leader in wafer-processing solutions for semiconductor, MEMS and nanotechnology applications. Through close collaboration with its global customers, the company implements its flexible manufacturing model to develop reliable, high-quality, low-cost-of-ownership systems that are easily integrated into customers’ fab lines. Key products include wafer bonding, lithography/nanoimprint lithography (NIL) and metrology equipment, as well as photoresist coaters, cleaners and inspection systems.

In addition to its dominant share of the market for wafer bonders, EVG holds a leading position in NIL and lithography for advanced packaging and MEMS. Along these lines, the company co-founded the EMC-3D consortium in 2006 to create and help drive implementation of a cost-effective through-silicon via (TSV) process for major ICs and MEMS/sensors. Other target semiconductor-related markets include silicon-on-insulator (SOI), compound semiconductor and silicon-based power-device solutions.

Founded in 1980, EVG is headquartered in St. Florian, Austria, and operates via a global customer support network, with subsidiaries in Tempe, Ariz.; Albany, N.Y.; Yokohama and Fukuoka, Japan; Seoul, Korea and Chung-Li, Taiwan. The company’s unique Triple i-approach (invent – innovate – implement) is supported by a vertical integration, allowing EVG to respond quickly to new technology developments, apply the technology to manufacturing challenges and expedite device manufacturing in high volume. More information is available at www.EVGroup.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology products such as StemDisc, and specifically those systems and products that are discussed in this press release. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

announced today that it has entered into a multi-year development and manufacturing agreement with EV Group, a 30 year old Austria-based leader in the nano-imprint lithography process designing and equipment manufacturing. The mutually exclusive two year agreement calls for EV Group and Shrink to develop and manufacture Shrink’s structured substrates for its StemDisc stem cell and cell culturing platform.

Some of the key design features of the StemDisc are:

1. Each StemDisc contains an eight-well footprint, and each well contains approximately 850 individual honeycomb shaped microwell cell culturing environments;
2. Each StemDisc microwell environment is approximately 450 microns across and over 100 microns deep, and is made from sub 200 micron thick optically transparent polymers, allowing the researchers’ microscope unprecedented access to the biological sample; and
3. The bottom aspect of the cell culturing environment is round, mimicking the natural shape of many of the tissue samples which may be studied in the StemDisc.

“We are pleased to announce Shrink’s relationship with EV Group, a world class nanotechnology applications developer and equipment manufacturer with a global presence. Over the past two years, Shrink StemDisc product footprint will serve as a platform for our entry into the growing cell culturing business. We believe that StemDisc offers unique competitive advantages relative to its peers and are excited as an organization as we roll out our initial products later this year and into the first quarter of next year,” said Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

Baum added, “Throughout the development process, we have counseled with EV Group and they have assisted us in creating manufacturing solutions that will allow Shrink to move from the prototype stage to the ability make many thousands of devices. As important, our relationship with EV Group has been structured for us to move beyond our initial product, the StemDisc450, as we add new products to the StemDisc family of products.”

EV Group VP and General Manager of North America stated, “Our Agreement with Shrink follows many months of work between Shrink’s StemDisc development group and our staff in Tempe, Arizona. Our team’s dedication to Shrink’s desire to create a robust process to manufacture many thousands of StemDisc devices in an efficient and cost effective process using EV Group’s state-of-the-art Application Lab has borne fruit as we begin to make devices as soon as the end of this year. This project will hopefully be one of many we work on with Shrink as EV Group leverages its significant intellectual capital in the form of process development for small and medium sizes business around the world.”

About EV Group

EV Group (EVG) is a world leader in wafer-processing solutions for semiconductor, MEMS and nanotechnology applications. Through close collaboration with its global customers, the company implements its flexible manufacturing model to develop reliable, high-quality, low-cost-of-ownership systems that are easily integrated into customers’ fab lines. Key products include wafer bonding, lithography/nanoimprint lithography (NIL) and metrology equipment, as well as photoresist coaters, cleaners and inspection systems.

In addition to its dominant share of the market for wafer bonders, EVG holds a leading position in NIL and lithography for advanced packaging and MEMS. Along these lines, the company co-founded the EMC-3D consortium in 2006 to create and help drive implementation of a cost-effective through-silicon via (TSV) process for major ICs and MEMS/sensors. Other target semiconductor-related markets include silicon-on-insulator (SOI), compound semiconductor and silicon-based power-device solutions.

Founded in 1980, EVG is headquartered in St. Florian, Austria, and operates via a global customer support network, with subsidiaries in Tempe, Ariz.; Albany, N.Y.; Yokohama and Fukuoka, Japan; Seoul, Korea and Chung-Li, Taiwan. The company’s unique Triple i-approach (invent – innovate – implement) is supported by a vertical integration, allowing EVG to respond quickly to new technology developments, apply the technology to manufacturing challenges and expedite device manufacturing in high volume. More information is available at www.EVGroup.com.

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology products such as StemDisc, and specifically those systems and products that are discussed in this press release. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

Shrink announced today that Shrink’s MetalFluor™ technology was studied, reported on and made the front cover of the November issue of Applied Physics Letters.

Below is a link to the online version of the article:

http://apl.aip.org/resource/1/applab/v97/i20/p203101_s1?isAuthorized=no

The Company’s technology and the work being performed by Dr. Michelle Khine, our scientific founder, continues to gain high praise from leading academic journals. The studies relate to potential commercial applications of this technology. Of note, the article states, “Because we have a range of nanostructure and nanogap sizes, we can ensure that we can achieve huge fluorescent enhancements on our substrate. These advantages show great potential for low-cost biomedical sensing at single molecular levels at physiological concentrations.” The Company believes that this article is further evidence that certain medical diagnostics tests, a multi-billion dollar annual industry in the United States alone, can provide physicians, patients and other medical professionals with better results using lower quantities of specimens using MetalFluor™ technologies.

Shrink intends to soon commercially offer the tools that Dr. Khine has used to achieve the results features in the most recent Applied Physics Letters. The Company intends to provide an additional update next week regarding our initial NanoShrink product and the related NanoShrink line, according to Mark L. Baum, Shrink’s CEO.

About Applied Physic Letters

Applied Physics Letters, published by the American Institute of Physics, features concise, up-to-date reports on significant new findings in applied physics. Emphasizing rapid dissemination of key data and new physical insights, Applied Physics Letters offers prompt publication of new experimental and theoretical papers bearing on applications of physics phenomena to all branches of science, engineering, and modern technology. Content is published online daily, collected into weekly online and printed issues (52 issues per year).

Simply put, nanotechnology is the study and development of components measuring 100 nanometers (one billionth of a meter) or less. At these dimensions, matter begins to exhibit different characteristics. Aluminum explodes on contact with the air. Carbon can become a one-dimensional material, and conduct electricity better than copper.

In the past ten years, the applied sciences field has been proliferated with companies devoted to the research of nanotechnology’s potential, and the development of products that showcase its capabilities to improve upon natural matter. Large chemical and manufacturing concerns have established nanotechnology arms to refine their production and remain competitive in their market. Smaller entities, with the eager help of public funding, have proven themselves strong with focused, product-specific innovations that prove nanotechnology’s value under the scrutiny of investors.

Nonetheless, it should be unsurprising that the stock market’s reflection of the nanotech industry should be unsteady. Between the relative novelty of the nanotech field, the number of start-ups represented among nanotech companies, and the nearly worldwide economic recession, a fair amount of ebb and flow in the longevity of individual companies is a reasonable expectation.

But with so much still to be grasped, and with such staggering innovations as nanotech companies have already generated in common products–self-regenerating car paint, stain-resistant fabrics, chemotherapy treatments that target diseased cells in the human body–it is best to look into nanotech companies as a long-term investment in an undeniably burgeoning field.

SHRINK NANOTECHNOLOGIES UNVEILS VIDEOS OF STEMDISC 450 PROTOTYPE GROWING HUMAN EMBYRONIC STEM CELLS

– Targets Q1 2011 for Roll-Out of Patent-Pending Biomedical Research Tool–

CARLSBAD, CA – November 5, 2010 – Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB:INKN), an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed working videos of its first product offering – the StemDisc450™, a high-yield, low cost, patent-pending cell culturing biomedical research tool. Shrink expects to begin offering this product for sale in the first quarter of 2011 or sooner.

“Tissue engineering and cell culturing are high growth areas of the biotechnology field. This trend is being fueled as the idea of “personalized medicine” – or “therapeutics and treatments made for you” – becomes a reality. And as the personalized medicine movement grows, biotech and pharmaceutical companies are focusing on the promise of novel research, especially new cellular-based therapies, to help combat cancer, spinal cord injuries, diabetes, Parkinson’s and Alzheimer’s disease, and many more. StemDisc is a platform for Shrink to offer a growing suite of products that will address an important spectrum of the needs within cellular and tissue engineering technologies and tools,” stated Mark L. Baum, CEO of Shrink Nanotechnologies, Inc.

“We are pleased to reveal a working StemDisc450 prototype, a device actually developing HESCs (human embryonic stem cells),” added Baum. “Shrink is exploring opportunities with established stem cell R&D companies for potential strategic partnerships for the sale and marketing of StemDisc™ products. Our primary target market is the more than 3,000 stem cell research labs and 15,000 biomedical laboratories operating in the United States.”

The videos are available by following this link:

http://www.shrinknano.com/stem-cell-culturing/

About StemDisc

StemDisc is designed to improve embryoid body (EB) formation of stem cells at a higher rate and efficiency over current EB formation methods. The platform can be used to grow and differentiate human and animal single cells, human embryonic stem cells (HESCs) and induced pluri-potent stem cells (IPSCs). Versions of StemDisc’s unique honeycomb-like well will be offered in different diameter and depth depending on the type of cell and application. Each round bottom “microwell” is capable of making 800 to 1,000 EBs, increasing the flexibility of use for researchers to achieve optimum EB formation with high reliability compared to legacy methods. A unique feature of the StemDisc product line is the optical transparency of the surface that the cells rest in. The StemDisc polymer offers amazing transparency, providing the cell biologist with the ability to see more of what she is doing as she completes her research. StemDisc’s five micron walls between microwells virtually assure a clean transfer of the biological material into a well – in a few easy steps, helping to further lower costs and accelerate the time to publish results of potentially life-saving studies. If you are interested in receiving more information about StemDisc, please contact us by visiting www.shrinknano.com.

About Shrink Nanotechnologies, Inc.
Shrink Nanotechnologies, Inc. is a one-of-a-kind FIGA™ organization, which focuses on leveraging contributions from experts in Finance, Industry, Government and Academia. Operating as a high-technology development-stage company, Shrink owns and develops proprietary and patent-pending nano-sized technologies, components and product systems. The Company’s unique NanoShrink™ material is a pre-stressed polymer which is used in a patent pending manufacturing platform with numerous applications in the solar energy, human and animal diagnostics, and biotechnology research and development tools industries. For more information, please visit www.shrinknano.com.
See also:

http://www.shrinksolar.com/blog/

http://www.shrinknano.com/products/product-tools

http://www.shrinknano.com/products/product-diagnostics

http://www.shrinknano.com/tech

http://www.shrinknano.com/tr35-a-children%E2%80%99s-toy-inspires-a-cheap-easy-production-method-for-high-tech-diagnostic-chips

Contact:
For Shrink Nanotechnologies
Mark L. Baum, Esq.
760-804-8844 x205

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only. Actual results may differ materially from those anticipated in this press release. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Shrink’s ability to obtain additional financing and to build and develop markets for Shrink’s biotechnology technologies and products. These factors should be strongly considered when making a decision to acquire or maintain a financial interest in Shrink, including consulting with a FINRA registered representative prior to making such decision. Shrink undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Shrink’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Shrink’s success are more fully disclosed in Shrink’s most recent public filings with the U.S. Securities and Exchange Commission.

“Long-term, nanotech has the potential to be as significant as the steam engine, the transistor and the Internet.” (Tom Kalil, former Deputy Assistant to President Clinton for Technology and Economic Policy)

Since its conceptual debut in 1959, nanotechnology has promised an amazing wealth of potential. The possibilities it suggests for uses as noble as space travel, to as mundane as car manufacturing, make it a front-running candidate for public and private investment.

The practical similarities of nanotechnology to biotechnology mirror their commercial paths, as nanotechnology allows similar strategies toward commercialization and investment opportunities.

In only the last ten years, initiatives such as the National Nanotechnology Initiative and the European Union Framework for Nanotechnology set the precedent in the western world for government funding in nanotechnology research. According to a study completed by Lux Research in 2004, the United States is putting more money into nanotechnology than any other country.

However, Asian companies are close behind, with such countries as Taiwan and South Korea bending their efforts toward the development of actual products improved by nanotechnology, such as magnetoresistive RAM, and display consoles for computer and television lighted by carbon nanotubes. Indeed, nanotechnology has launched a new friendly competition among nations, similar to the international space race of the middle 20th century.